First National Trust Co lessened its holdings in Danaher Co. (NYSE:DHR) by 21.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,177 shares of the conglomerate’s stock after selling 1,154 shares during the period. First National Trust Co’s holdings in Danaher were worth $388,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in DHR. Vanguard Group Inc. raised its position in shares of Danaher by 1.3% in the second quarter. Vanguard Group Inc. now owns 41,488,407 shares of the conglomerate’s stock valued at $3,501,206,000 after buying an additional 520,776 shares during the last quarter. BlackRock Inc. raised its position in shares of Danaher by 3.2% in the second quarter. BlackRock Inc. now owns 39,201,798 shares of the conglomerate’s stock valued at $3,308,239,000 after buying an additional 1,233,876 shares during the last quarter. FMR LLC raised its position in shares of Danaher by 0.9% in the second quarter. FMR LLC now owns 19,624,350 shares of the conglomerate’s stock valued at $1,656,100,000 after buying an additional 183,183 shares during the last quarter. Parnassus Investments CA raised its position in shares of Danaher by 0.3% in the third quarter. Parnassus Investments CA now owns 9,796,584 shares of the conglomerate’s stock valued at $840,351,000 after buying an additional 29,381 shares during the last quarter. Finally, Flossbach Von Storch AG raised its position in shares of Danaher by 17.2% in the third quarter. Flossbach Von Storch AG now owns 6,776,921 shares of the conglomerate’s stock valued at $581,324,000 after buying an additional 994,902 shares during the last quarter. 76.19% of the stock is currently owned by institutional investors.
A number of equities analysts have recently weighed in on the stock. Argus boosted their price objective on shares of Danaher from $100.00 to $115.00 and gave the company a “buy” rating in a research report on Thursday, February 1st. Royal Bank of Canada reissued a “hold” rating and issued a $98.00 price objective on shares of Danaher in a research report on Wednesday, January 31st. Stifel Nicolaus upped their price target on shares of Danaher from $110.00 to $115.00 and gave the stock a “buy” rating in a research report on Wednesday, January 31st. Morgan Stanley upped their price target on shares of Danaher from $103.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 31st. Finally, Credit Suisse Group upped their price target on shares of Danaher from $99.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $100.13.
In other Danaher news, SVP Daniel Raskas sold 37,870 shares of the stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $93.33, for a total transaction of $3,534,407.10. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Angela S. Lalor sold 42,988 shares of the stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $102.29, for a total transaction of $4,397,242.52. Following the transaction, the senior vice president now owns 82,008 shares in the company, valued at $8,388,598.32. The disclosure for this sale can be found here. Insiders have sold a total of 274,913 shares of company stock worth $27,729,293 over the last quarter. 12.20% of the stock is currently owned by insiders.
Shares of Danaher Co. (DHR) traded up $2.30 during mid-day trading on Friday, hitting $94.46. 3,684,046 shares of the stock traded hands, compared to its average volume of 2,870,000. The stock has a market capitalization of $65,710.00, a P/E ratio of 26.99, a PEG ratio of 1.99 and a beta of 1.04. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.39. Danaher Co. has a fifty-two week low of $78.97 and a fifty-two week high of $104.82.
Danaher (NYSE:DHR) last announced its earnings results on Tuesday, January 30th. The conglomerate reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.16 by $0.03. The business had revenue of $5.09 billion during the quarter, compared to the consensus estimate of $4.97 billion. Danaher had a net margin of 13.60% and a return on equity of 11.36%. The business’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.05 earnings per share. research analysts forecast that Danaher Co. will post 4.37 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, January 26th. Shareholders of record on Friday, December 29th were paid a dividend of $0.14 per share. The ex-dividend date was Thursday, December 28th. This represents a $0.56 dividend on an annualized basis and a yield of 0.59%. Danaher’s dividend payout ratio (DPR) is 16.00%.
TRADEMARK VIOLATION NOTICE: “Danaher Co. (DHR) Shares Sold by First National Trust Co” was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://ledgergazette.com/2018/02/12/first-national-trust-co-has-388000-holdings-in-danaher-co-dhr.html.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.